Case Reports

A POST-PARTUM WOMAN WITH DYSPNEA
Saaron Laighold, MD
A G1P1 40 year-old Caucasian female without significant past
medical history presented to an outside hospital with worsening
shortness of breath and hemoptysis. The patient was 10 days
status post caesarian section for preeclampsia. Her course after
delivery was complicated by a stay in the ICU for shortness of
breath. She was discharged home 7 days post-delivery and then
returned to the hospital 3 days later. The patient was intubated at
the outside hospital for hypoxia (O2 sats of 50% on room air)
and transferred to TJUH for further management.
The patient’s family history was significant for her father being
deceased at age 40 from an MI and her mother being alive and
well. The patient lives at home with her husband and her child
who is healthy and well. She has no history of drug, alcohol, or
cigarette smoking.
Prior to delivery her medications included multivitamin, folate,
and ferrous sulfate. After delivery, the patient was discharged
home on metoprolol extended release 25 mg, furosemide, and
hydralazine. Upon transfer to TJUH she was on a dobutamine
drip, propofol drip, nitroglycerin drip, and intravenous enalapril.
The patient was transferred to the TJUH CCU already intubated
and sedated. Vitals signs were stable with temperature of 97.8F,
pulse of 105, respiratory rate of 19 and blood pressure of 143/78.
The physical exam was significant for jugular venous distension
to 15cm, presence of a third heart sound (S3), soft systolic ejection
murmur, bilateral coarse breath sounds, and 2+ lower extremity
edema to her knees.
Laboratory values including CBC, chemistry panel, cardiac
enzymes and electrolytes were normal at time of transfer. BNP
was 158, protein was 4.7 g/L, and albumin 2.9 g/L. Urinalysis
revealed 3+ blood and trace ketones while serum cortisol was 17.5
and TSH was 1.95 mIU/mL.
Studies at the outside hospital showed no pulmonary embolus on
CT scan of the chest and no deep vein thrombosis by lower
extremity dopplers. Echocardiogram revealed left ventricular
ejection fraction of 25-30% and moderate to severe mitral
regurgitation. Chest x-ray on arrival to TJUH was consistent with
pulmonary edema as shown below (Figure 1).
Differential diagnosis included peripartum cardiomyopathy,
accelerated hypertension, diastolic dysfunction, systemic
infection, pulmonary embolism, preeclampsia, amniotic fluid
embolus, or cardiomyopathy due to infection; ischemia; or
toxicity. The time course, clinical presentation, and studies helped
to narrow in on the etiology of her symptoms.
The patient presented 10 days post-partum with signs of left-sided
congestive heart failure with a decreased ejection fraction on her
echocardiogram. The fact that the patient presented in the postpartum period rather than earlier in her pregnancy would seem to
eliminate an underlying cardiomyopathy. Her echocardiogram
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revealed systolic dysfunction making diastolic dysfunction
unlikely to be the cause for this woman’s symptoms. She was ruled
out for a pulmonary embolus and did not have any signs of
systemic infections or indications of an underlying ischemia to
account for the new onset cardiomyopathy.
Amniotic fluid embolism can cause hypoxia in the post-partum
period. However, the onset of symptoms typically presents during
labor and delivery or within the first 48 hours after delivery as
opposed to symptoms of severe hypoxia 10 days after delivery, as
was the case with this patient. Also, patients with amniotic fluid
embolism will typically present with disseminated intravascular
coagulation and symptoms similar patients with anaphylactic or
septic shock.
Preeclampsia and accelerated hypertension were though to be
implausible causes in this case because the patient did not present
with severe hypertension at the time of her severe hypoxia. The
patient’s symptoms of preeclampsia should have improved after
delivery instead of causing her to become hypoxic 10 days post delivery.
The patient’s presentation was thought to be consistent with
peripartum cardiomyopathy. She was treated for congestive heart
failure with intravenous furosemide and ACE inhibitor along with
the dobutamine and nitrates. After several days of diuresis, a repeat
echocardiogram revealed mild to moderate mitral regurgitation,
moderate left atrium enlargement, and an ejection fraction of 4045% with mild global LV dysfunction. The patient was extubated
after several days and transferred to a telemetry floor. She
continued to improve with medical treatment for her heart failure.
The patient was discharged home on an ACE inhibitor, betablocker and diuretics with the recommendation that she avoid
future pregnancies.
The patient had several risk factors for the condition including
older maternal age and the development of preeclampsia during
her pregnancy. The improvement in symptoms and the
improvement in LVEF with supportive therapy were consistent
with a peripartum cardiomyopathy as opposed to other causes for
her presentation.

Discussion
Peripartum cardiomyopathy (PPCM) was first described in the
1700s and first defined in 1937. It is a rare form of dilated
cardiomyopathy of unknown etiology which affects women in
late pregnancy or early post-partum. The true incidence of this
condition is unknown but it is thought to be 1 per 3000 to 1 per
4000 live births or between 1000 and 1300 women each year in
the US. For unknown reasons, the incidence of PPCM is higher
in certain regions of the world. In one area of Haiti the incidence
is estimated to be 1 in 300 pregnancies.
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cocaine abese, nutritional deficiencies including Selenium, and long
term oral tocolytic therapy with Beta-agonists such as terbutaline.

Figure 1. CXR showing pulmonary edema.
Peripartum cardiomyopathy is defined by cardiac failure within
the last month of pregnancy or within 5 months postpartum. The
condition is characterized by the absence of other causes of
congestive heart failure and the lack of heart disease prior to the
last month of pregnancy. Most patients with PPCM present with
symptoms of congestive heart failure within the first 4 months
post-partum (78%). 9% of patients present in the last month
before delivery while 13% present more than 1 month antepartum
or more than 4 months postpartum. The time course for
peripartum cardiomyopathy contrasts with the time for
presentation of congestive heart failure due to other etiologies.
The 2nd trimester of pregnancy is the greatest hemodynamic
burden of gravid state and most patients with underlying cardiac
dysfunction tend to develop symptoms of heart failure at this
time. Normal pregnancy causes increased blood volume, increased
cardiac output and decreased afterload so that patients with
underlying cardiac disease present earlier during pregnancy than
patients with PPCM.

While the etiology of PPCM remains elusive, investigation of
women with PPCM and associated risk factors has led to identification of several possible etiologies. Viral myocarditis is one
suspected cause of PPCM. Studies have reported the incidence of
myocarditis among PPCM patients to be from 9% to 78%. Some
studies have estimated the incidence of myocarditis to be similar to
controls with idiopathic dilated cardiomyopathy while other studies
have estimated the incidence of myocarditis to be much higher
among patients with PPCM. The variation among study results is
thought to be due differences in the timing of myocardial biopsies
and due to variations in the definition of myocarditis used by
pathologists. Investigators have speculated that pregnancy may
increase patient susceptibility to viral myocarditis leading to PPCM.
It has been postulated that PPCM may be caused by an
autoimmune reaction. Supporting evidence for this theory
includes the finding that high titers of autoantibodies against
cardiac tissue proteins have been identified in women with
PPCM. The suspected autoimmune mechanism is that fetal cells
escape into the maternal circulation and take up residence in
cardiac tissue triggering an autoimmune reaction against the
myocardium. After delivery, it is theorized, the fetal cells in the
myocardium are recognized as nonself when the autoimmunosuppresion of pregnancy subsides and the patient’s immune
system attacks the cardiac myocytes causing cardiomyopathy.

Patients are judged to have PPCM after they present in congestive
heart failure within the last month of pregnancy or within the
first 5 months postpartum. By echo criteria, women with PPCM
have LVEF<45%, decreased fractional shortening<30%, and
end/diastolic dimension>2.7 cm/m3. Symptoms for congestive
heart failure in patients with peripartum cardiomyopathy are
similar to heart failure symptoms for patients with other etiologies
of CHF. Symptoms include dyspnea, orthopnea, PND, MR
murmur. Physical exam signs include cardiomegaly, S3, JVD,
peripepheral edema, arrhythmias, and pulmonary rales.

Other theories for the etiology of PPCM include systemic
inflammation, hormonal involvement and nutritional
deficiencies. Inflammation is believed to be involved in the
pathogenesis of PPCM as it does in other etiologies of CHF.
TNF-alpha, IL-6, Fas/APO-1 are significantly elevated in patients
with PPCM compared to controls. FAS: apoptosis-signaling
receptor is significantly elevated in patients who died from PPCM
as compared to controls. Relaxin is an ovarian hormone produced
during pregnancy which is thought to play a role in PPCM.
Relaxin has positive inotropic and chonotropic properties and
abnormalities of this hormone are speculated to participate in the
pathogenesis of PPCM. Nutritional deficiencies, especially
selenium deficiency have been found among women with PPCM.
In one area of Haiti where PPCM is exceptionally common
pregnant women commonly suffer from nutritional deficiencies.
Selenium deficiency may play a role in the pathogenesis of PPCM
because it may make the heart more susceptible to injury from
viruses, hypertension, or hypocalcemia.

While the cause of peripartum cardiomyopathy remains unknown
a number of risk factors are associated with the development of the
condition. Risk factors include age greater than 30 years,
multiparity, women of African descent, pregnancy with multiple
fetuses, history of preeclampsia, eclampsia, postpartum HTN,

Therapy for PPCM involves standard heart failure management
including diuretics, inotropes, and blood pressure control.
Management of PPCM in the antepartum period must account
for possible teratogenecity of certain medications typically used
for heart failure patients. ACE inhibitors are contraindicated in
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pregnancy and so they should be avoided. Hydralazine and
nitrates are safer to use for blood pressure therapy. Similarly,
anticoagulation to prevent the risk of embolism formation should
avoid coumadin in the antepartum period because of its possible
teratogenecity. Both heparin and coumadin should be safe to use
postpartum because neither are excreted into breast milk. If the
diagnosis of PPCM is made in the antepartum period, delivery
should be strongly considered because of the risk of continuing
the pregnancy to both the fetus and the mother.
PPCM has a high incidence of serious morbidity and mortality
with listed mortality rates between 18% and 56%. Complications
from PPCM include arrhythmias, progressive heart failure
necessitating BiV pacemaker and defibrillator implantation or
heart transplant, and thromboembolism. Clot formation is an
important complication with an incidence which has been reported
to be as high as 50%. The high frequency of thromboembolism is
due to the hypercoaguable state of late pregnancy, stasis and
turbulent blood flow in dilated cardiomyopathy and the common
practice of placing patients in late pregnancy on bed rest.
The outcome for women with PPCM is extremely varied with
the serious consequences of the condition usually occurring in
the months following the diagnosis. In some patients with PPCM,
clinical and echocardiographic status improves quickly and returns
to normal. Other patients deteriorate rapidly necessitating device
implantation or transplantion. Still others, will respond to therapy
and have persistent signs of cardiac dysfunction. US mortality
ranges from 25% to 50% with close to 50% of deaths occurring
in the first 3 months postpartum.
Women who do recover usually do so within 6 months of the
diagnosis and a substantial number of affected women will have
significant improvement within the first 6 months. In one study,
50% of patients with PPCM had resolution of cardiomegaly and
LV dysfunction at 6 months after delivery without reported
cardiac mortality. Patients with persistent cardiac abnormalities at
6 months after delivery had a mean survival of 4.7 years and an
85% mortality at 5 years.

Left ventricular size and severity of left ventricular dysfunction are
related to worsening outcomes in the acute and subacute phase
following the development of PPCM. Poor outcome is associated
with worsening LV size and dysfunction, higher parity, being an
older patient, and later onset of symptoms following the pregnancy.
Future pregnancies for women with PPCM carry substantial risk.
Small studies have shown that women with PPCM have worse
outcomes in future pregnancies compared to normal patients even
if their left ventricular size and function has returned to normal.
Studies have shown worse outcomes for mother and fetus in
women with persistent LV dysfunction as compared to women
with PPCM who have regained normal function. In one NEJM
study, in women with PPCM who regained normal function 25%
of future pregnancies were associated with cardiac dysfunction. In
patients with persistent left ventricular dysfunction, 50% of
subsequent pregnancies were associated with worsening cardiac
dysfunction. Table 1 shows that women with PPCM had a high
incidence of maternal complications during subsequent pregnancy
with a higher incidence among those whose LV function had not
recovered from the initial pregnancy.
Fetal health has also been found to be worse among women with
PPCM in future pregnancies. In the NEJM study, of the women
who had regained normal function 13% of women delivered
prematurely. In women with continued left ventricular
dysfunction, 50% of pregnancies ended in premature births and
25% of the patients required therapeutic abortions.
■

References
1. de Beus, et al.“Peripartum Cardiomyopathy: a condition intensivists should be aware
of.” Intensive Care Medicine. (2003) 29:167-174.
2. Elkayam, etal. “Maternal and Fetal Outcomes of Subsequent Pregnancies in Women
with Peripartum Cardiomyopathy.” NEJM. May 24, 2001, Number 21, Volume
344:1567-71.
3. Hibbard, JU, Lindheimer, M, Lang, RM. “A modified definition for peripartum
cardiomyopathy and prognosis based on echocardiography.” Obstetrics &
Gynecology. 1999;94:311-316.
4. Pearson GD, Veille, JC, Rahimtoola, S, et al “Peripartum cardiomyopathy” National
Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of
Health) workshop recommendations and review.. JAMA 2000 Mar 1;283(9):1183-8.
5. UptoDate.com
6. Reimold, Sharon, “Peripartum Cardiomyopathy.” NEJM. May 24, 2001, Number
21, Volume 344:1629-1630.

9

